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Summary
Objectives: To examine the circumstances, features and
management of anaphylaxis in children and adults.
Design: Self-completed questionnaire.
Participants: The age of participants ranged from 0 to 72
years.
Setting: We analysed data from self-completed question-
naires collected over a 12-year period, i.e. 2001–2013,
available to people by phone and, since 2012, for online
completion through the Anaphylaxis Campaign.
Main outcome measure: We analysed data from self-com-
pleted questionnaires collected over a 12- year period, i.e.
2001-2013, available to people by phone and, since 2012,
for online completion through the Anaphylaxis Campaign
Results: In total, 356 questionnaires were submitted, of
which 54 did not meet the criteria for anaphylaxis. The
remaining 302 anaphylactic reactions originated from 243
individuals; 193 (64%) of these reactions were in children.
Approximately half of all reactions occurred at home
(n¼ 148; 49%); 61% (n¼ 193) of reactions occurred in
those reporting a history of asthma, and many (n¼ 76;
41%) of these individuals had asthma that they classified
as being severe. In 57% (n¼ 173) cases, the respondent
reacted to a known allergen. Self-injectable adrenaline (epi-
nephrine) was available in 79% of the cases, and it was only
used in 38% of episodes. The usage of self-injected adren-
aline was lower in children (30%) than in adults (54%), even
though 82% of children had adrenaline available at the time
of the reaction compared to 74% of adults.
Conclusions: These data suggest that the majority of ana-
phylaxis reactions are triggered by exposure to known food
allergens and that approximately half of these reactions
occur at home. Access to self-injectable adrenaline was
sub-optimal and when available it was only used in a minor-
ity of cases. Avoiding triggers, access to self-injectable
adrenaline and its prompt use in the context of reactions
need to be reinforced.
Keywords
anaphylaxis, allergy, asthma, adrenaline, food allergens, pre-
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Introduction
There have been substantial increases in the numbers of
hospital admissions from anaphylaxis noted in the UK
over recent decades,1–3 thus reﬂecting a probable
increase in lifetime risk.4 Similar increases have been
noted in other parts of the world.5,6 Many of these reac-
tions occur in thosewith known allergies and thus reﬂect
failures in prevention and/or appropriate emergency
when reactions occur.7 It is now recognised that these
reactions commonly occur in community settings.8 In
order to inform deliberations on how best to minimise
the risk of anaphylaxis and optimise the self-manage-
mentof reactions, it is therefore important tounderstand
patient perspectives and experiences of such reactions.9
We sought to obtain such insights through analysis of a
unique dataset compiled by theAnaphylaxis Campaign,
aUK-wide patient charity that provides advice and sup-
port to patients/carers experiencing anaphylaxis and
their healthcare professionals.
Thisworkbuilds onaprevious report byUguz et al.,10
which reported an analysis of 109 individuals who
reported on 126 reactions up until April 2001. The pre-
vious study concluded that the presence of asthma in
children led to particularly severe reactions and that
self-injectable adrenaline (epinephrine) was under-used,
even when readily available. In the present study, we
analysed data collected by the Anaphylaxis Campaign
over the following 12-year period, i.e. 2001–2013.
Methods
Ethical considerations
The study was processed and approved by the
University of Edinburgh’s ethical committee. The
Medical Advisory Committee of the Anaphylaxis
Campaign had previously approved the format of
the ﬁnal version of the questionnaire used in this study.
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Recruitment and data collection
We used the same self-completed questionnaire that
was used in the earlier survey.10 These self-completed
questionnaires were collected over the period May
2001–September 2013.
Individuals calling the Anaphylaxis Campaign’s
Helpline were made aware of the survey, and a
copy was sent by post for carer/self-completion to
those expressing an interest in participating. From
2012 onwards, it was also made available for online
completion through the Anaphylaxis Campaign’s
website (www.anaphylaxis.org.uk/).
The questionnaire comprised 41 questions, of
which approximately half were multiple choice in
nature (see Appendix 1). These questions enquired
about demographic information and relevant health
and medical considerations such as the presence of
known allergies. Participants were also asked to pro-
vide a description of the reaction that they were
reporting; this description included details of the sus-
pected allergen, the symptoms experienced, available
treatments, treatments used and whether the reaction
resulted in a hospital attendance.
Data processing and analysis
We ﬁrst sought to determine if the reaction that was
described was likely to have been anaphylaxis. This
assessment was made by establishing whether there
was evidence of a systemic allergic reaction in which
respiratory and/or cardiovascular symptoms were
also present.11 Those responses that were judged unli-
kely to represent anaphylaxis were not interrogated
any further.
Data from probable reports of anaphylaxis were
entered into and analysed using Microsoft Excel. For
the purposes of this study, children were deﬁned as
those aged 0–16 years and adults were deﬁned as
those aged 17 years and over. Co-existent asthma
was categorised as being severe if it was reported as
causing waking at night; it was otherwise classiﬁed as
mild-to-moderate.
Data were summarised using counts and percent-
ages with accompanying 95% conﬁdence intervals
(CIs), where appropriate.
Results
In total, 356 questionnaires were submitted to the
Anaphylaxis Campaign; 54 of these reports were
excluded as they were judged unlikely to be reports
of anaphylaxis. The following sections relate to the
302 reports that were judged to describe anaphylaxis.
These 302 reports came from 243 unique individuals.
Of these, 228 individuals provided a single report; the
remaining 15 individuals provided a total of 74
reports with these individuals submitting between 2
and 25 incident reports.
Demographic characteristics of respondents
The age of those experiencing reactions ranged from
0 to 72 years with a mean age of 19.1 years (SD 16.6).
Sixty-four percent (n¼ 193; 95% CI 0.58–0.69) of
responses related to children; the remaining 36% of
reports (n¼ 109; 95% CI 0.31–0.42) were in adults
(i.e. aged 16–72 years).
Of the 243 unique respondents, 58% (n¼ 140) were
female and of these 42% (n¼ 59) occurred in girls. Of
the 103 (42%) unique male respondents, 80% (n¼ 82)
of reactions occurred in boys.
In total, 53% (n¼ 160) of the reactions were
reported by females; there were comparatively fewer
reports of reactions in girls (n¼ 72; 37%) than boys
(n¼ 121; 63%), but this pattern reversed in adults
with women reporting a greater proportion of reac-
tions (n¼ 88; 81%) than men (n¼ 21; 19%).
Presence of coexistent asthma
Sixty-one percent (n¼ 185; 95% CI 0.56–0.67) of all
reports involved people with co-existent asthma; in
41% of these reports (n¼ 76; 95% CI 0.34–0.49),
the asthma was categorised as being severe.
Setting of reaction and triggers
Forty-nine percent (n¼ 148) of reactions occurred
whilst at home. Similar proportions of children
and adults experienced reactions whilst at home (chil-
dren: 53%, n¼ 103; 95% CI 0.46–0.61; adults: 41%,
n¼ 45; 95% CI 0.32–0.51).
Of the 90 children’s reactions that occurred out-
side of the home environment, 26% (n¼ 23; 95% CI
0.17–0.36) occurred whilst at nursery or school.
A further 18% of reactions (n¼ 16; 95% CI 0.11–
0.27) occurred whilst eating out at a cafe´ or restaur-
ant and four reactions (4%; 95% CI 0.01–0.11)
occurred in hospital.
Sixty-four reactions in adults occurred outside of
their homes; 31% (n¼ 20; 95% CI 0.20–0.44)
occurred in a cafe´ or restaurant; 13% (n¼ 8; 95%
CI 0.06–0.23) occurred whilst at work and 6%
(n¼ 4; 95% CI 0.02–0.15) occurred whilst in hospital.
Fifty-seven percent (173; 95% CI 0.51–0.63) of
reactions were triggered by exposure to a known
allergen. The most common known allergen was
tree nuts, which accounted for 39% (n¼ 67) of
these reactions to known triggers. Peanuts accounted
for 29% (n¼ 51) of these reactions, milk/dairy
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products for 11% (n¼ 19) and egg for 9% (n¼ 16).
Non-food triggers described included inhalant aller-
gens (grass, dust, cat, dog and horse), stinging insects
(wasp and mosquito), drugs (antibiotics, aspirin,
paracetamol and anaesthetics) and latex.
Self-management, hospital attendance/admission
and outcomes
Although in the majority of cases (n¼ 240; 79%, 95%
CI 0.74–0.84), self-injectable adrenaline (epinephrine)
was available, it was only administered in 38%
(n¼ 92; 95% CI 0.32–0.45) of cases.
Availability of self-injectable adrenaline was com-
parable in children (n¼ 159; 82%, 95% CI 0.76–0.87)
and adults (n¼ 81; 74%, 95% CI 0.65–0.82). Children
with available adrenaline were however less likely to
receive/use it (n¼ 48; 30%; 95% CI 0.23–0.38) than
adults 54% (n¼ 44; 95% CI 0.43–0.65).
Adults were more likely (n¼ 64; 59%, 95% CI
0.49–0.68) to be treated in hospital than children
(n¼ 79; 41%, 95% CI 0.34–0.48). Twenty percent
(n¼ 39; 95% CI 0.15–0.27) of children and 28%
(n¼ 31; 95% CI 0.20–0.38) of adults were admitted
to hospital.
There were no fatalities reported in this dataset.
Discussion
Statement of principal findings
This study has found that most cases of anaphylaxis
being reported to the Anaphylaxis Campaign followed
exposure to known food triggers at home or in other
community settings. Reactions were more common in
children, with important age-sex diﬀerences being
found such that reactions were more common in
male children and in adult females. Although there
was access to self-injectable adrenaline in the majority
of cases, it was only used in aminority of cases.Overall,
under half of all reactions involved hospital attendance
with fewer still resulting in admission. There were no
fatalities reported.
Strengths and limitations
A key strength of this study is that it involved
carers/individuals personally reporting details of
their reactions onto a standard data collection form
that had been previously scrutinised by a scientiﬁc
committee and used in an earlier investigation.10
There are however a number of limitations that
need to be considered when interpreting the ﬁndings
from this research. Key amongst these was that the
sample was self-selected raising concerns about the
generalisability of the ﬁndings. Furthermore, it was
not possible within the context of this study to valid-
ate the carer/self-reports of triggers, clinical features
or self-management.
Interpretation of the findings in the light of previous
research
This study echoes the ﬁndings from earlier research
that the majority of reactions occur in community
settings following exposure to known triggers.7,8,10
In keeping with previous research, reactions were
common in males in childhood, with this pattern
reversing in adults.12 It was of concern that approxi-
mately half of all reactions occurred in individuals
with a history of asthma; this is because co-existent
asthma is known to substantially increase the risk of
poor outcomes from anaphylaxis.13,14 A relatively
high proportion of individuals had access to adren-
aline, this possibly reﬂecting the fact that this study
was undertaken in those who were aware of/members
of the Anaphylaxis Campaign – but this only trans-
lated into use of self-injectable adrenaline in a minor-
ity of cases.15 Further studies are needed to explore
why patients do not readily use adrenaline and why
they are reluctant to present at hospital. That all indi-
viduals survived, despite sub-optimal management in
a number of cases, reﬂects the now known low case
fatality ratio from anaphylaxis.16
Implications for policy, practice and future research
This work highlights the importance of providing
patients with appropriate allergen advice and further-
more the need for support that will help them to
implement this in the context of the complexities of
everyday life. UK, European and international ana-
phylaxis guidelines all make clear the importance of
having access to and prompt use of self-injectable
adrenaline in the context of reactions, and there is
therefore a need for health professionals to reinforce
this message at regular intervals.17–21 This is import-
ant because the severity of reactions and fatalities can
be diﬃcult to predict, hence the need for prompt self-
treatment.22,23 Guidelines also encourage a period of
observation under medical care following a reaction
and so individuals experiencing reactions should be
advised to seek urgent medical attention whenever
they experience anaphylaxis.17–21
Further research is needed to assess the generalis-
ability of the ﬁndings from this work and this would
ideally be done by prospectively following a cohort of
individuals who record their reactions. This work
also suggests that many episodes of anaphylaxis go
unreported to medical attention. Such episodes need
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therefore to be taken into account in future studies
into the epidemiology of anaphylaxis using routinely
collected healthcare data. Finally, there is a need for
further interventional studies which aim to improve
the eﬀectiveness of avoidance measures and self-care
when avoidance measures fail.24
Conclusions
Many of the concerns highlighted by the previous
survey persist, these including the failure of avoid-
ance measures and inadequate carer/self-management
in the context of experiencing anaphylaxis. There is a
need for intervention studies designed to reduce the
risk of recurrent reactions and to optimise self-man-
agement in the event of further reactions.
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